These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 10957937)

  • 21. Experts Opinion on the Practical Use of Azathioprine and 6-Mercaptopurine in Inflammatory Bowel Disease.
    Mottet C; Schoepfer AM; Juillerat P; Cosnes J; Froehlich F; Kessler-Brondolo V; Seibold F; Rogler G; Vavricka SR; Michetti P
    Inflamm Bowel Dis; 2016 Nov; 22(11):2733-2747. PubMed ID: 27760078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits?
    Su CG; Stein RB; Lewis JD; Lichtenstein GR
    Dig Liver Dis; 2000; 32(6):518-31. PubMed ID: 11057928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paediatric inflammatory bowel disease: review with a focus on practice in low- to middle-income countries.
    Dalzell AM; Ba'Ath ME
    Paediatr Int Child Health; 2019 Feb; 39(1):48-58. PubMed ID: 30900526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 6-mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine.
    Domènech E; Nos P; Papo M; López-San Román A; Garcia-Planella E; Gassull MA
    Scand J Gastroenterol; 2005 Jan; 40(1):52-5. PubMed ID: 15841714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Inflammatory bowel disease--diagnosis and therapy].
    Vogt W
    Praxis (Bern 1994); 2005 Feb; 94(5):145-50. PubMed ID: 15745379
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
    Amin J; Huang B; Yoon J; Shih DQ
    Inflamm Bowel Dis; 2015 Feb; 21(2):445-52. PubMed ID: 25248004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A national survey on the patterns of treatment of inflammatory bowel disease in Canada.
    Hilsden RJ; Verhoef MJ; Best A; Pocobelli G
    BMC Gastroenterol; 2003 Jun; 3():10. PubMed ID: 12791168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone density improves with disease remission in patients with inflammatory bowel disease.
    Reffitt DM; Meenan J; Sanderson JD; Jugdaohsingh R; Powell JJ; Thompson RP
    Eur J Gastroenterol Hepatol; 2003 Dec; 15(12):1267-73. PubMed ID: 14624148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Refractory IBD: medical management.
    Tremaine WJ
    Neth J Med; 1997 Feb; 50(2):S12-4. PubMed ID: 9050327
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring of AZA/6-MP treatment in children with IBD is necessary.
    Dubinsky MC
    Inflamm Bowel Dis; 2003 Nov; 9(6):386-8; discussion 392-3. PubMed ID: 14671488
    [No Abstract]   [Full Text] [Related]  

  • 31. The genetics of inflammatory bowel disease: diagnostic and therapeutic implications.
    Cuffari C
    World J Pediatr; 2010 Aug; 6(3):203-9. PubMed ID: 20706819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy.
    Boulton-Jones JR; Pritchard K; Mahmoud AA
    Aliment Pharmacol Ther; 2000 Dec; 14(12):1561-5. PubMed ID: 11121903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenomics and IBD: TPMT and thiopurines.
    Sandborn WJ
    Inflamm Bowel Dis; 2004 Feb; 10 Suppl 1():S35-7. PubMed ID: 15168829
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine.
    Su C; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):209-34, viii. PubMed ID: 15177535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Biomarkers in the diagnosis and therapy of inflammatory bowel diseases].
    Iijima H; Shinzaki S; Tsujii M; Takehara T
    Nihon Rinsho; 2012 May; 70(5):869-73. PubMed ID: 22620015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of Pediatric Inflammatory Bowel Disease Unclassified (IBD-U): Incorporated With Serological and Gene Expression Profiles.
    Chandradevan R; Hofmekler T; Mondal K; Harun N; Venkateswaran S; Somineni HK; Ballengee CR; Kim MO; Griffiths A; Noe JD; Crandall WV; Snapper S; Rabizadeh S; Rosh JR; Walters TD; Bertha M; Dubinsky MC; Denson LA; Sauer CG; Markowitz JF; LeLeiko NS; Hyams JS; Kugathasan S
    Inflamm Bowel Dis; 2018 Sep; 24(10):2285-2290. PubMed ID: 29860529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Familial occurrence and inheritance studies in inflammatory bowel disease.
    Binder V; Orholm M
    Neth J Med; 1996 Feb; 48(2):53-6. PubMed ID: 8819799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetics and inflammatory bowel disease: progress and prospects.
    Ho GT; Lees C; Satsangi J
    Inflamm Bowel Dis; 2004 Mar; 10(2):148-58. PubMed ID: 15168816
    [No Abstract]   [Full Text] [Related]  

  • 39. Inflammatory bowel disease in pediatric patients.
    Marx G; Seidman EG
    Curr Opin Gastroenterol; 1999 Jul; 15(4):322-5. PubMed ID: 17023965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural history and outcome of inflammatory bowel diseases in children in Saudi Arabia: A single-center experience.
    Alreheili KM; Alsaleem KA; Almehaidib AI
    Saudi J Gastroenterol; 2018; 24(3):171-176. PubMed ID: 29676289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.